Society for Participatory Medicine
JANUARY 27, 2022
My mission of advocacy was widened and deepened upon my stage IV colorectal cancer diagnosis in 2014 when I shared my expertise with others fighting for scans and treatments. It builds trust to uncover unmet needs, provide solutions, and yield powerful, measurable results.
Digital Health Global
AUGUST 22, 2024
Spellman and Wortel are the most recent additions to Catawba Research’s team of scientific and regulatory advisors who support sponsors across a multitude of therapeutic areas and provide clinical development and regulatory strategy across North America, Europe and Asia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lloyd Price
DECEMBER 8, 2018
Craig Venter in 2014—at around $310 million, according to a Human Longevity regulatory filing obtained by Lagniappe Labs LLC, whose Prime Unicorn Index tracks valuations of privately held companies. But key facets of its business didn’t develop as planned, say people familiar with the company.
Healthcare IT Today
NOVEMBER 14, 2022
The new financing will be used to accelerate the organization’s rapid expansion, including growing its team of talent and expanding its product research and development function. Within Life Sciences, the firm focuses on MedTech, Diagnostics, and Opportunistic Drug Development. For more information, visit www.mtngp.com.
Lloyd Price
JUNE 17, 2023
History of Livongo Livongo was founded in 2014 by Glen Tullman, who was the former CEO of Allscripts Healthcare Solutions. Here are some of the key milestones in Livongo's history: 2014: Livongo is founded by Glen Tullman. This could create a company that is able to develop and deliver personalized treatments to patients.
Lloyd Price
FEBRUARY 18, 2024
Understanding and Development (1990s-2000s): 1990s: Research delves into the GLP-1 receptor and its role in regulating metabolism. 2014: Liraglutide becomes the first GLP-1 RA approved for weight management. 1996: Studies suggest GLP-1's potential in managing type 2 diabetes and obesity.
Insulin Nation
JUNE 4, 2019
SGLT2 Development and Method of Action. Ever since the first SGLT2 inhibitor (dapagliflozin) was approved by the EU in 2011 and the USA in 2014, it and another nine gliflozin drugs developed since then have been considered for (off-label) use in Type-1 diabetes, as well as in Type-2 diabetes for which they were first approved.
Expert insights. Personalized for you.
97 
Let's personalize your content